The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Autoimmune Inner Ear Disease Clinical Trial

Official title:
An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01950312
Study type	Interventional
Source	XOMA (US) LLC
Contact
Status	Completed
Phase	Phase 2
Start date	August 2013
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01526174` - Intratympanic Injection for Autoimmune Inner Ear Disease	Phase 1/Phase 2
Completed	`NCT01267994` - A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease	Phase 1/Phase 2
Recruiting	`NCT03587701` - Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease	Phase 2
Recruiting	`NCT04806282` - Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets